SELVITA
Research SELVITA (SLV.WA) on Bullrun: market cap PLN 401.90M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLV.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyPLN
- Market capPLN 401.90M
- Financial periodQ1 2026
- RevenuePLN 75.83M
- Net income-PLN 5.45M
- Free cash flowPLN 5.24M
- Gross margin78.1%
Valuation Snapshot
latest market cap is PLN 401.90M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 364.25M | PLN 813.00K | PLN 66.10M | 80.6% | n/a | PLN 24.22M | PLN 169.57M | PLN 321.73M |
| FY2022 | PLN 407.46M | PLN 32.61M | n/a | n/a | 1.7 | PLN 74.16M | PLN 125.85M | PLN 262.18M |
| FY2021 | PLN 310.92M | PLN 18.22M | n/a | n/a | 0.8 | PLN 83.55M | PLN 92.19M | PLN 196.87M |
| FY2020 | PLN 137.36M | PLN 19.92M | n/a | n/a | 1.05 | PLN 93.01M | PLN 4.64K | PLN 152.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-11 | PLN 401.90M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About SELVITA
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SELVITA's market cap?
SELVITA's market capitalization is PLN 401.90M.
What does SELVITA do?
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety.